Warning: Saxagliptin/Onglyza/Kombiglyze XR

The FDA has announced that they are studying diabetes drug Saxagliptin, marketed as Onglyza and Kombiglyze XR, for possible cardiovascular side effects.  They are not recommending label changes at this time.  For details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm385471.htm.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s